Calithera Biosciences, Inc. (CALA)

NASDAQ: CALA · IEX Real-Time Price · USD
0.365
-0.045 (-10.95%)
At close: Feb 1, 2023, 4:00 PM
0.340
-0.025 (-6.85%)
After-hours: Feb 1, 2023, 7:59 PM EST
-10.95%
Market Cap 1.78M
Revenue (ttm) n/a
Net Income (ttm) -84.93M
Shares Out 4.87M
EPS (ttm) -26.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 782,291
Open 0.400
Previous Close 0.410
Day's Range 0.303 - 0.400
52-Week Range 0.303 - 13.380
Beta 1.33
Analysts Buy
Price Target 5.10 (+1,296.88%)
Earnings Date Mar 29, 2023

About CALA

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chro... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2014
Employees 63
Stock Exchange NASDAQ
Ticker Symbol CALA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CALA stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 1,296.88% from the latest price.

Price Target
$5.1
(1,296.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of ...

3 weeks ago - GlobeNewsWire

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 --

2 months ago - GlobeNewsWire

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's thi...

3 months ago - GlobeNewsWire

Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate

Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small c...

4 months ago - Market Watch

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation Enrollment ongoing in Phase 2 stu...

4 months ago - GlobeNewsWire

3 Penny Stocks With Surprisingly Superior Fundamentals

The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks.

Other symbols: BRQSVZLA
5 months ago - InvestorPlace

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan M...

5 months ago - GlobeNewsWire

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 --

6 months ago - GlobeNewsWire

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's sec...

6 months ago - GlobeNewsWire

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with  relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored...

7 months ago - GlobeNewsWire

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, In...

7 months ago - GlobeNewsWire

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes

7 months ago - GlobeNewsWire

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has f...

8 months ago - GlobeNewsWire

Calithera to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Mol...

9 months ago - GlobeNewsWire

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: ...

9 months ago - GlobeNewsWire

Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Compa...

9 months ago - GlobeNewsWire

Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds

Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers

10 months ago - GlobeNewsWire

Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022

10 months ago - GlobeNewsWire

Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount

Calithera Biosciences Inc (NASDAQ: CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million. Each share of common ...

11 months ago - Benzinga

Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing ...

11 months ago - GlobeNewsWire

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it inte...

11 months ago - GlobeNewsWire

Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Com...

11 months ago - GlobeNewsWire

Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting

First data from preclinical synthetic lethality program of novel VPS4A inhibitors with potential for clinical advancement in variety of cancers First data from preclinical synthetic lethality program ...

11 months ago - GlobeNewsWire

Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Mo...

1 year ago - GlobeNewsWire

AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases ...

1 year ago - PRNewsWire